These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 7578526)

  • 1. Different organization of von Willebrand factor oligomers in type-2A and -2B von Willebrand disease variants: effects of DDAVP infusion and protease inhibitors.
    Casonato A; Pontara E; Bertomoro A; Dannhauser D; Secchiero S; Zaninotto M; Girolami A
    Ann Hematol; 1995 Oct; 71(4):189-94. PubMed ID: 7578526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.
    Casonato A; Pontara E; Dannhäuser D; Bertomoro A; Sartori MT; Girolami A
    Haematologia (Budap); 1994; 26(2):97-109. PubMed ID: 7890268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal collagen binding activity of 2A von Willebrand factor: evidence that the defect depends only on the lack of large multimers.
    Casonato A; Pontara E; Bertomoro A; Zucchetto S; Zerbinati P; Girolami A
    J Lab Clin Med; 1997 Feb; 129(2):251-9. PubMed ID: 9016863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
    Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
    Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of desmopressin on von Willebrand factor multimers in Doberman Pinschers with type 1 von Willebrand disease.
    Callan MB; Giger U; Catalfamo JL
    Am J Vet Res; 2005 May; 66(5):861-7. PubMed ID: 15938072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The heterogeneity of type IIA von Willebrand's disease: studies with protease inhibitors.
    Batlle J; Lopez Fernandez MF; Campos M; Justica B; Berges C; Navarro JL; Diaz Cremades JM; Kasper CK; Dent JA; Ruggeri ZM
    Blood; 1986 Dec; 68(6):1207-12. PubMed ID: 3490883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test.
    Michiels JJ; Smejkal P; Penka M; Batorova A; Pricangova T; Budde U; Vangenechten I; Gadisseur A
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):518-531. PubMed ID: 27443694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A probable double heterozygous type II von Willebrand's disease with increased ristocetin induced platelet aggregation.
    Kinoshita S; Yoshioka K; Kasahara M; Takamiya O
    Am J Hematol; 1992 Jul; 40(3):192-8. PubMed ID: 1609773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Von Willebrand factor collagen binding activity in the diagnosis of von Willebrand disease: an alternative to ristocetin co-factor activity?
    Casonato A; Pontara E; Bertomoro A; Sartorello F; Cattini MG; Girolami A
    Br J Haematol; 2001 Mar; 112(3):578-83. PubMed ID: 11260057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal proteolytic degradation of von Willebrand factor after desmopressin infusion in a new subtype of von Willebrand disease (ID).
    Lopez-Fernandez MF; Gonzalez-Boullosa R; Blanco-Lopez MJ; Perez M; Batlle J
    Am J Hematol; 1991 Mar; 36(3):163-70. PubMed ID: 1996556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals.
    Batlle J; Lopez-Fernandez MF; Lopez-Borrasca A; Lopez-Berges C; Dent JA; Berkowitz SD; Ruggeri ZM; Zimmerman TS
    Blood; 1987 Jul; 70(1):173-6. PubMed ID: 3496131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to DDAVP in children with von Willebrand disease type 2.
    Schneppenheim R; Budde U; Beutel K; Hassenpflug WA; Hauch H; Obser T; Oyen F; Schneppenheim S; Schrum J
    Hamostaseologie; 2009 May; 29(2):143-8. PubMed ID: 19404524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Mechanistic Model to Quantify von Willebrand Factor Release, Survival and Proteolysis in Patients with von Willebrand Disease.
    Ferrari M; Galvanin F; Barolo M; Daidone V; Padrini R; Bezzo F; Casonato A
    Thromb Haemost; 2018 Feb; 118(2):309-319. PubMed ID: 29378356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.